An interventional study of video support in Lung Cancer, sponsored by Assistance Publique Hopitaux De Marseille. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Assistance Publique Hopitaux De Marseille · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 400 studies in Lung Neoplasms with a site in France — 114 open to participants now, 150 under way, 26 of them phase 3. Lung Neoplasms · France.
Among the 400 studies in Lung Neoplasms with a site in France, this one is the 124th largest by planned enrollment of the 291 interventional ones that give a count, is one of 31 that started in 2024, is one of 110 with no phase, reaches primary completion later than 79 of the 149 other live ones, and was the 336th registered.
5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.
Browse Lung Neoplasms studies →114 of the 400 studies in Lung Neoplasms with a site in France are open now. Recruiting first, the newest first:
Centre Leon Berard · Sites in France
Ages 18+
University Hospital, Brest · Sites in France
Ages 18+
Centre Hospitalier Henri Duffaut - Avignon · Sites in France
Ages 18+
SystImmune Inc. · Sites in France, United States, Australia and 13 more countries
Ages 18+
Bristol-Myers Squibb · Sites in France, United States, Belgium and 10 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
400 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 49 · Phase 2 88 · Phase 3 69 · Phase 4 8
First in 1993; this study’s year is marked. 31 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 226 is above the median of 60 across 3,668 interventional studies indexed under Lung Neoplasms.
Median enrollment 170 across the 291 interventional studies, 190 across the 105 observational. Of the 217 that completed or were terminated, 49 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
144 of 400 have an industry lead sponsor. The 10 most frequent:
Assistance Publique Hopitaux De Marseille is the lead sponsor of 702 studies on the registry; 139 are open to participants now.
Assistance Publique Hopitaux De Marseille has 7 studies filed under Lung Neoplasms — fewer than ten, so there is no comparison to draw.
34 of the studies in Lung Neoplasms with a site in France that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06151574Phase 3Boehringer IngelheimBeamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment | 2026-12-10 |
| NCT04380636Phase 3Merck Sharp & Dohme LLCStudy of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) | 2027-05-05 |
| NCT05920356Phase 3AmgenA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | 2027-06-30 |
| NCT06635824Phase 3GenmabTrial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) | 2027-07-30 |
| NCT06119581Phase 3Eli Lilly and CompanyA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | 2027-11 |
Add all 34 to your calendar (.ics) → With an account.
Among the 400 studies in Lung Neoplasms with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Uni-centric, randomized, open-label, prospective interventional-comparative study, with a control arm (patients receiving standard preoperative information) and an experimental arm (patients receiving standard preoperative information and having access to a dematerialized educational video support).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
for therapeutic purposes (in the case of proven tumor histology) or for diagnostic and therapeutic purposes (in the absence of proven histology, but strong suspicion, after validation by RCP),
- Patients who have given their consent.
Exclusion Criteria:
Other: video support
video support provided to the patient before surgery
Immediate pre-operative anxiety
self-measurement using the HAD Scale
Time frame: 10 days
Perioperative anxiety (randomization (consultation), immediate postoperative and discharge)
based on HAD scale
Time frame: 90 days
Post-traumatic stress disorder
PCL-5 scale
Time frame: 90 days
Quality of life evaluation
European Organisation for Research and Treatment of Cancer core health- related quality of life questionnaire (QLQ-C30).
Time frame: 90 days
Cumulative postoperative morbidity
score CCI
Time frame: 90 days
Intra-hospital consumption of analgesics
accounting for in-hospital consumption of analgesics
Time frame: 90 days
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2024 (actual). Primary completion is estimated for Jan 2028, 42 months after the start.
Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 42 months is above that.
Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Jan 2026 → Jan 2028 and completion Apr 2026 → Apr 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique Hopitaux De Marseille →